Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Pierre Raynaud

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
The Prostate|September 15, 2017
Sexual steroids in serum and prostatic tissue of human non-cancerous prostate (STERPROSER trial)Yann Neuzillet, Jean-Pierre Raynaud, Camélia Radulescu, et al.
Asian Journal of Andrology|March 25, 2021
Relationship of preoperative androgen levels and metabolic syndrome with quality of life and erectile function in patients who are to undergo radical prostatectomyYann Neuzillet, Jean-François Dreyfus, Jean-Pierre Raynaud, et al.
Asian Journal of Andrology|February 10, 2021
Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomyYann Neuzillet, Mathieu Rouanne, Jean-François Dreyfus, et al.
The Prostate|October 30, 2018
Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial)Matthias E Meunier, Yann Neuzillet, Jean-Pierre Raynaud, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|August 23, 2002
[Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]Frans Debruyne, Gary Koch, Peter Boyle, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 14, 2008
Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa)Frank Giton, Alexandre de la Taille, Yves Allory, et al.
European Urology|June 21, 2002
Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international studyFrans Debruyne, Gary Koch, Peter Boyle, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|September 18, 2004
[Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis]Frans Debruyne, Peter Boyle, Fernando Calais da Silva, et al.
European Urology|May 20, 2004
Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysisFrans Debruyne, Peter Boyle, Fernando Calais Da Silva, et al.
European Urology Oncology|August 29, 2024
Final Results of the ANDROCAN Study: Histopathological Characteristics and Biochemical Recurrence at 5 Years of Localized Prostate Cancer According to Preoperative Gonadal StatusYann Neuzillet, Jean-Pierre Raynaud, Jean-François Dreyfus, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
The Prostate|September 15, 2017
Sexual steroids in serum and prostatic tissue of human non-cancerous prostate (STERPROSER trial)Yann Neuzillet, Jean-Pierre Raynaud, Camélia Radulescu, et al.
Asian Journal of Andrology|March 25, 2021
Relationship of preoperative androgen levels and metabolic syndrome with quality of life and erectile function in patients who are to undergo radical prostatectomyYann Neuzillet, Jean-François Dreyfus, Jean-Pierre Raynaud, et al.
Asian Journal of Andrology|February 10, 2021
Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomyYann Neuzillet, Mathieu Rouanne, Jean-François Dreyfus, et al.
The Prostate|October 30, 2018
Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial)Matthias E Meunier, Yann Neuzillet, Jean-Pierre Raynaud, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|August 23, 2002
[Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]Frans Debruyne, Gary Koch, Peter Boyle, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 14, 2008
Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa)Frank Giton, Alexandre de la Taille, Yves Allory, et al.
European Urology|June 21, 2002
Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international studyFrans Debruyne, Gary Koch, Peter Boyle, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|September 18, 2004
[Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis]Frans Debruyne, Peter Boyle, Fernando Calais da Silva, et al.
European Urology|May 20, 2004
Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysisFrans Debruyne, Peter Boyle, Fernando Calais Da Silva, et al.
European Urology Oncology|August 29, 2024
Final Results of the ANDROCAN Study: Histopathological Characteristics and Biochemical Recurrence at 5 Years of Localized Prostate Cancer According to Preoperative Gonadal StatusYann Neuzillet, Jean-Pierre Raynaud, Jean-François Dreyfus, et al.
Pageof 4